IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients

The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent assays (ELISAs) to measure the cytokine interleukin-17A (IL-17A) in the serum of ALS patients (n = 32; 28 sporadic ALS (sALS) and 4 familial ALS (fALS)) and control subjects (n = 14; 10 healthy subjects and 4 with autoimmune disorders). IL-17A serum concentrations were 5767 ± 2700 pg/ml (mean ± SEM) in sALS patients and 937 ± 927 pg/ml in fALS patients in comparison to 7 ± 2 pg/ml in control subjects without autoimmune disorders (p = 0.008 ALS patients vs. control subjects by Mann-Whitney test). Sixty-four percent of patients and no control subjects had IL-17A serum concentrations > 50 pg/ml (p = 0.003 ALS patients vs. healthy subjects by Fisher's exact test). The spinal cords of sALS (n = 8), but not control subjects (n = 4), were infiltrated by interleukin-1β- (IL-1β-), and tumor necrosis factor-α-positive macrophages (co-localizing with neurons), IL-17A-positive CD8 cells, and IL-17A-positive mast cells. Mononuclear cells treated with aggregated forms of wild type superoxide dismutase-1 (SOD-1) showed induction of the cytokines IL-1β, interleukin-6 (IL-6), and interleukin-23 (IL-23) that may be responsible for induction of IL-17A. In a microarray analysis of 28,869 genes, stimulation of peripheral blood mononuclear cells by mutant superoxide dismutase-1 induced four-fold higher transcripts of interleukin-1α (IL-1α), IL-6, CCL20, matrix metallopeptidase 1, and tissue factor pathway inhibitor 2 in mononuclear cells of patients as compared to controls, whereas the anti-inflammatory cytokine interleukin-10 (IL-10) was increased in mononuclear cells of control subjects. Aggregated wild type SOD-1 in sALS neurons could induce in mononuclear cells the cytokines inducing chronic inflammation in sALS spinal cord, in particular IL-6 and IL-17A, damaging neurons. Immune modulation of chronic inflammation may be a new approach to sALS.

[1]  J. Haines,et al.  Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.

[2]  J S Valentine,et al.  Reactions of Hydrogen Peroxide with Familial Amyotrophic Lateral Sclerosis Mutant Human Copper-Zinc Superoxide Dismutases Studied by Pulse Radiolysis* , 1998, The Journal of Biological Chemistry.

[3]  M. Swash,et al.  El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis , 2000, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[4]  J. Elliott.  Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. , 2001, Brain research. Molecular brain research.

[5]  M. Graves,et al.  Cyclooxygenase-2-positive Macrophages Infiltrate the Alzheimer's Disease Brain and Damage the Blood–brain Barrier Pathology and Laboratory , 2022 .

[6]  B. Ransom,et al.  Increased cytotoxic potential of microglia from ALS‐transgenic mice , 2004, Glia.

[7]  N. Shibata,et al.  Ultrastructural study of aggregates in the spinal cord of transgenic mice with a G93A mutant SOD1 gene , 2005, Acta Neuropathologica.

[8]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[9]  T. Siddique,et al.  Presence of dendritic cells, MCP‐1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue , 2004, Annals of neurology.

[10]  H. Vinters,et al.  Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[11]  F. Turkheimer,et al.  Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study , 2004, Neurobiology of Disease.

[12]  Borries Demeler,et al.  Dissociation of Human Copper-Zinc Superoxide Dismutase Dimers Using Chaotrope and Reductant , 2004, Journal of Biological Chemistry.

[13]  K. Hensley,et al.  Journal of Neuroinflammation Primary Glia Expressing the G93a-sod1 Mutation Present a Neuroinflammatory Phenotype and Provide a Cellular System for Studies of Glial Inflammation , 2022 .

[14]  D. Cleveland,et al.  ALS: A Disease of Motor Neurons and Their Nonneuronal Neighbors , 2006, Neuron.

[15]  M. Salmona,et al.  Insoluble Mutant SOD1 Is Partly Oligoubiquitinated in Amyotrophic Lateral Sclerosis Mice* , 2006, Journal of Biological Chemistry.

[16]  J. Edmonds,et al.  Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort). , 2006, Arthritis and rheumatism.

[17]  A. Sik,et al.  Chromogranin-mediated secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis , 2006, Nature Neuroscience.

[18]  H. Weiner,et al.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.

[19]  J. Boyce.  Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation , 2007, Immunological reviews.

[20]  D. Gruol,et al.  Physiological and pathological roles of interleukin-6 in the central nervous system , 1997, Molecular Neurobiology.

[21]  G. Rouleau,et al.  Oxidized/misfolded superoxide dismutase‐1: the cause of all amyotrophic lateral sclerosis? , 2007, Annals of neurology.

[22]  Bryan F. Shaw,et al.  How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? , 2007, Trends in biochemical sciences.

[23]  D. Ganea,et al.  Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. , 2007, Arthritis and rheumatism.

[24]  Hiromu Ito,et al.  Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model , 2007, The Journal of experimental medicine.

[25]  F. Sallusto,et al.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. , 2007, Nature immunology.

[26]  R. Bowser,et al.  Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosis , 2007, Proceedings of the National Academy of Sciences.

[27]  M. Tsai,et al.  Immunomodulatory mast cells: negative, as well as positive, regulators of immunity , 2008, Nature Reviews Immunology.

[28]  Julian P. Whitelegge,et al.  Initiation and elongation in fibrillation of ALS-linked superoxide dismutase , 2008, Proceedings of the National Academy of Sciences.

[29]  M. Weinand,et al.  Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy , 2009, Acta Neuropathologica.

[30]  B. Li,et al.  IL-17-Producing Alveolar Macrophages Mediate Allergic Lung Inflammation Related to Asthma1 , 2008, The Journal of Immunology.

[31]  Jia Newcombe,et al.  Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. , 2008, The American journal of pathology.

[32]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[33]  V. Silani,et al.  Metalloproteinase alterations in the bone marrow of ALS patients , 2010, Journal of Molecular Medicine.

[34]  E. Lubberts,et al.  Interleukin-23 is critical for full-blown expression of a non-autoimmune destructive arthritis and regulates interleukin-17A and RORγt in γδ T cells , 2009, Arthritis research & therapy.

[35]  J. Valentine,et al.  Aggregation of copper-zinc superoxide dismutase in familial and sporadic ALS. , 2009, Antioxidants & redox signaling.

[36]  D. Souza,et al.  Interleukin-6 Serum Levels in Patients with Parkinson’s Disease , 2009, Neurochemical Research.

[37]  Amit Awasthi,et al.  Th17 cells: from precursors to players in inflammation and infection. , 2009, International immunology.

[38]  M. Colombo,et al.  Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation. , 2009, Blood.

[39]  J. Julien,et al.  Extracellular mutant SOD1 induces microglial‐mediated motoneuron injury , 2010, Glia.

[40]  S. Pileri,et al.  Immunopathology and Infectious Diseases Mast Cells and Th 17 Cells Contribute to the Lymphoma-Associated Pro-Inflammatory Microenvironment of Angioimmunoblastic T-Cell Lymphoma , 2010 .

[41]  Jeffery N Agar,et al.  Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS , 2010, Nature Neuroscience.

[42]  Todd Davidson,et al.  Generation of Pathogenic Th17 Cells in the Absence of TGF-β Signaling , 2010, Nature.

[43]  Johan Jacobsson,et al.  Novel Antibodies Reveal Inclusions Containing Non-Native SOD1 in Sporadic ALS Patients , 2010, PloS one.

[44]  S. Raychaudhuri,et al.  SCID MOUSE MODEL OF PSORIASIS: A UNIQUE TOOL FOR DRUG DEVELOPMENT OF AUTOREACTIVE T-CELL AND TH-17 CELL-MEDIATED AUTOIMMUNE DISEASES , 2010, Indian journal of dermatology.

[45]  M. Michalopoulou,et al.  Interleukin‐17 and interleukin‐23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? , 2010, Acta neurologica Scandinavica.

[46]  Michel Dib,et al.  Biomarkers in Amyotrophic Lateral Sclerosis , 2009, Molecular Diagnosis & Therapy.